REAL-LIFE EFFECTIVENESS OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Dominguez, L. [1 ]
Valera-Rubio, M. [2 ]
Madronal, Carrion, I [1 ]
机构：
[1] Hosp Virgen Macarena, Seville, SE, Spain
[2] Hosp Univ Virgen Macarena, Seville, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO99
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [11] Ibrutinib for Chronic Lymphocytic Leukemia REPLY
    Burger, Jan A.
    Styles, Lori
    Kipps, Thomas J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (16): : 1594 - 1595
  • [12] Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1440): : 29 - 30
  • [13] Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study
    Visentin, Andrea
    Mauro, Francesca Romana
    Cibien, Francesca
    Vitale, Candida
    Reda, Gianluigi
    Fresa, Alberto
    Ciolli, Stefania
    Pietrasanta, Daniela
    Marchetti, Monia
    Murru, Roberta
    Gentile, Massimo
    Rigolin, Gian Matteo
    Quaglia, Francesca Maria
    Scarfo, Lydia
    Sportoletti, Paolo
    Pravato, Stefano
    Piazza, Francesco
    Coscia, Marta
    Laurenti, Luca
    Molica, Stefano
    Foa, Robin
    Cuneo, Antonio
    Trentin, Livio
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E95 - E99
  • [14] Ibrutinib As First Line Therapy in Chronic Lymphocytic Leukemia Patients over 80 Years Old: A Retrospective Real-Life Multicenter Italian Cohort
    Martino, Enrica Antonia
    Mauro, Francesca Romana
    Reda, Gianluigi
    Laurenti, Luca
    Visentin, Andrea
    Frustaci, Annamaria
    Vigna, Ernesto
    Pepe, Sara
    Catania, Gioacchino
    Loseto, Giacomo
    Murru, Roberta
    Chiarenza, Annalisa
    Sportoletti, Paolo
    Del Principe, Maria Ilaria
    Coscia, Marta
    Galimberti, Sara
    Tedeschi, Alessandra
    Rossi, Davide
    Trentin, Livio
    Morabito, Fortunato
    Gattei, Valter
    Gentile, Massimo
    [J]. BLOOD, 2023, 142
  • [15] Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort
    Martino, Enrica Antonia
    Mauro, Francesca Romana
    Reda, Gianluigi
    Laurenti, Luca
    Visentin, Andrea
    Frustaci, Annamaria
    Vigna, Ernesto
    Pepe, Sara
    Catania, Gioacchino
    Loseto, Giacomo
    Murru, Roberta
    Chiarenza, Annalisa
    Sportoletti, Paolo
    Del Principe, Maria Ilaria
    Laureana, Roberta
    Coscia, Marta
    Galimberti, Sara
    Ferretti, Eleonora
    Zucchetto, Antonella
    Bomben, Riccardo
    Polesel, Jerry
    Tedeschi, Alessandra
    Rossi, Davide
    Trentin, Livio
    Neri, Antonino
    Morabito, Fortunato
    Gattei, Valter
    Gentile, Massimo
    [J]. HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
  • [16] Ibrutinib Resistance in Chronic Lymphocytic Leukemia
    Furman, Richard R.
    Cheng, Shuhua
    Lu, Pin
    Setty, Menu
    Perez, Alexendar R.
    Guo, Ailin
    Racchumi, Joelle
    Xu, Guozhou
    Wu, Hao
    Ma, Jiao
    Steggerda, Susanne M.
    Coleman, Morton
    Leslie, Christina
    Wang, Y. Lynn
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (24): : 2352 - 2354
  • [17] Ibrutinib for the treatment of chronic lymphocytic leukemia
    Farooqui, Mohammed Z. H.
    Wiestner, Adrian
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (11): : 925 - 933
  • [18] The Use of Ibrutinib in Chronic Lymphocytic Leukemia
    Damon, Lloyd E.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 154 - 156
  • [19] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kang, Dong-Won
    Wang, Li
    Short, Nicholas J.
    Ferrajoli, Alessandra
    Wang, Yucai
    Zhou, Shouhao
    Shen, Chan
    [J]. PHARMACOECONOMICS, 2024, 42 (04) : 409 - 418
  • [20] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Dong-Won Kang
    Li Wang
    Nicholas J. Short
    Alessandra Ferrajoli
    Yucai Wang
    Shouhao Zhou
    Chan Shen
    [J]. PharmacoEconomics, 2024, 42 : 409 - 418
12345